KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

被引：13
|
作者：
Nanda, R.
Specht, J.
Dees, C.
Berger, R.
Gupta, S.
Geva, R.
Pusztai, L.
Pathiraja, K.
Ray, A.
Karantza, V.
Buisseret, L.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ North Carolina Lineberger Comprehens Canc Ct, Chapel Hill, NC USA
[4] Sheba Med Ctr, Tel Hashomer, Israel
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[7] Yale Univ Sch Med, New Haven, CT 06520 USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LCCC 1525: A phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (mTNBC)
    Anders, C. K.
    Moore, D.
    Sambade, M.
    Cuaboy, L.
    Garrett, A.
    Woodcock, M.
    McKinnon, K.
    Cowens, K.
    Bortone, D.
    Calhoun, B.
    Carey, L.
    Dees, C.
    Jolly, T.
    Muss, H.
    Reeder-Hayes, K.
    Kaltman, R.
    Jankowitz, R.
    Gudena, V.
    Olajide, O.
    Perou, C.
    Vincent, B.
    Serody, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [32] A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)
    Isakoff, Steven J.
    Tung, Nadine M.
    Yin, Jun
    Tayob, Nabihah
    Parker, Joanne
    Rosenberg, Julie
    Bardia, Aditya
    Spring, Laura
    Park, Hannah
    Collins, Maya
    Barry, William T.
    Severgnini, Mariano
    Peterkin, Doris
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    BMC MEDICINE, 2022, 20 (01)
  • [35] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    BMC Medicine, 20
  • [36] Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.
    Sohn, Joohyuk
    Kim, Gun Min
    Lee, Keun Seok
    Kim, Sung-Bae
    Kim, Jee Hung
    Ahn, Hee Kyung
    Lee, Jieun
    Park, Kyong Hwa
    Kim, Jee Hyun
    Lee, Kyoung Eun
    Shin, Eui-Cheol
    Park, Su-Hyung
    Yang, Se Hwan
    Heo, MinKyu
    Woo, Jung Won
    Sung, Young Chul
    Im, Young Hyuck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
    Vinayak, Shaveta
    Tolaney, Sara M.
    Schwartzberg, Lee Steven
    Mita, Monica M.
    McCann, Georgia Anne-Lee
    Tan, Antoinette R.
    Hendrickson, Andrea Elisabeth Wahner
    Forero-Torres, Andres
    Anders, Carey K.
    Wulf, Gerburg M.
    Dillon, Patrick M.
    Lynce, Filipa
    Zarwan, Corrine
    Erban, John Kalil
    Dezube, Bruce Jeffrey
    Zhou, Yinghui
    Buerstatte, Nathan
    Arora, Sujata
    Achour, Haroun
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)
    Page, David B.
    Kim, Isaac K.
    Sanchez, Katherine
    Moxon, Nicole
    Mellinger, Staci L.
    Conlin, Alison Katherine
    Acheson, Anupama Kurup
    Perlewitz, Kelly Shea
    Lewis, Stacy K.
    Kemmer, Kathleen A.
    Mitri, Zahi Ibrahim
    Basho, Reva K.
    Riffle, Emily
    Ahn, Jenny
    Pucilowska, Joanna
    Martel, Maritza
    Urba, Walter John
    McArthur, Heather L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Immunogenomic evolution and atypical response to atezolizumab in a patient with metastatic triple-negative breast cancer (mTNBC)
    Molinero, Luciana
    Li, Yijin
    Chang, Ching-Wei
    Maund, Sophia
    Berg, Maureen
    Harrison, Jeanne
    Fasso, Marcella
    O'Hear, Carol
    Hegde, Priti S.
    Emens, Leisha A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [40] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
12345